It is widely publicized that amyloid in the brain may not be the best agent for gauging progression and severity of Alzheimer’s disease. Tau imaging seems to hold greater promise in that arena. What does this mean for amyloid imaging?

The timing for performing breast MR diffusion-tensor imaging (DTI) is not restricted throughout the menstrual cycle, though the modulations in diffusion parameters due to hormone replacement therapy (HRT) and lactation should be taken into account in DTI evaluation, according to a study published in the June issue of Radiology.

Human epidermal growth factor receptor 2 (HER2) biomarkers have been the standard for imaging agents that target hormonally active breast cancers that tend to be very aggressive. Now researchers have developed an alternative and potentially more comprehensive biomarker of disease, HER3, according to a study presented during this week’s Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting, which was held June 7-11 in St. Louis.

This past week, about 4,000 attendees gathered in St. Louis for the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting. This year marked the 60th anniversary of the meeting, and as always there was plenty of ground breaking research unveiled.

A new CT technique that uses the Veo algorithm and filtered back projection (FBP) could screen for cancers like mesothelioma using less radiation by creating detailed pictures from CT scans, according to a study published online May 30 by BMJ Open. 

An emerging radiotracer homes in on prostate-specific anatomy and finds elusive lesions, according to a study presenting this year at the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting.

The combination of late-life depression and beta-amyloid deposition may lead to a quickening of neurodegeneration and progressive Alzheimer’s disease, according to a study presented during the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting, which concludes today.

MRI studies have revealed that moderate and late preterm babies—born 32 to 36 weeks into gestation—have similar brain abnormalities as those of very preterm infants born prior to 32 weeks of gestation.